All In Biotech

Drug Trial Radar · NCT00985660

Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets (30 mg; Mylan) and Sular® Extended Release Tablets (30 mg; First Horizon) in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 28, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Jun 2007

Primary completion

Jul 2007

Study completion Jul 2007

Sponsor

Lead sponsor
Mylan Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Sep 28, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy adult subjects under fasting conditions.

Conditions

  • Healthy

Interventions

  • Nisoldipine Extended-release Tablets, 30 mgDrug

    1 x 30 mg Tablet under fasting conditions

  • Sular® Extended Release Tablets, 30 mgDrug

    1 x 30 mg Tablet under fasting conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration time curveTime frame: Serial plasma samples collected for up to 72 hours post-dose
  2. Maximum Plasma ConcentrationTime frame: Serial plasma samples collected up to 72 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRACS Institute Ltd.

    Fargo, North Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.